ESSA Pharma Inc
NASDAQ:EPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ESSA Pharma Inc
Stock-Based Compensation
ESSA Pharma Inc
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ESSA Pharma Inc
NASDAQ:EPIX
|
Stock-Based Compensation
$1.1m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-2%
|
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Stock-Based Compensation
CA$3.2m
|
CAGR 3-Years
54%
|
CAGR 5-Years
82%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Stock-Based Compensation
$14.7m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
16%
|
|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Stock-Based Compensation
$53.7m
|
CAGR 3-Years
38%
|
CAGR 5-Years
57%
|
CAGR 10-Years
31%
|
|
|
Eupraxia Pharmaceuticals Inc
TSX:EPRX
|
Stock-Based Compensation
CA$8.8m
|
CAGR 3-Years
103%
|
CAGR 5-Years
120%
|
CAGR 10-Years
N/A
|
|
|
e
|
enGene Holdings Inc
NASDAQ:ENGN
|
Stock-Based Compensation
$9.6m
|
CAGR 3-Years
332%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ESSA Pharma Inc
Glance View
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.
See Also
What is ESSA Pharma Inc's Stock-Based Compensation?
Stock-Based Compensation
1.1m
USD
Based on the financial report for Jun 30, 2025, ESSA Pharma Inc's Stock-Based Compensation amounts to 1.1m USD.
What is ESSA Pharma Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
-2%
Over the last year, the Stock-Based Compensation growth was -80%. The average annual Stock-Based Compensation growth rates for ESSA Pharma Inc have been -50% over the past three years , -30% over the past five years , and -2% over the past ten years .
